Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

Features - Cultivation

Trial How – Oil CBD Free PURE Works :Endocannabinoids CBD Does

Xenusoid
30.05.2018

Content:

  • Trial How – Oil CBD Free PURE Works :Endocannabinoids CBD Does
  • Does CBD oil work for chronic pain management?
  • What is CBD and What Medical Conditions Might It Help?
  • Mar 16, In this article, we look at how CBD oil works and how it can be used to Unlike other cannabinoids — such as tetrahydrocannabinol (THC) . In addition, using CBD oil with other medications may make those medications more or less Almost all research on CBD oil and pain comes from adult trials. Numerous alkaloids were isolated in pure form or partially characterized. .. However, in other clinical trials, cannabinoids appeared to reduce tremor but were but not after taking nabilone tablets or orally administered capsules containing cannabis oil. . THC improved motor control in a patient with musician's dystonia. Jun 12, Med Cannabis Cannabinoids ;–72 a cannabis user, and it can be used discretely even in a social setting, e.g., at work or around family. CBD product Epidiolex®, which is currently in phase 3 trials with . This means that enriching a natural hemp extract with pure (often synthetic) CBD makes.

    Trial How – Oil CBD Free PURE Works :Endocannabinoids CBD Does

    Recent studies in animal models and in the clinic suggest that CB1 receptor antagonists could prove useful in the treatment of both parkinsonian symptoms and levodopa-induced dyskinesia, whereas CB1 receptor agonists could have value in reducing levodopa-induced dyskinesia. This effect was significantly reduced by coinjection with the cannabinoid receptor agonist WIN 55, The simultaneous administration of the CB1 antagonist rimonabant with quinpirole and WIN 55, blocked the effect of WIN 55, on quinpirole-induced alleviation of akinesia.

    This effect was also reversed by rimonabant. The injection of 0. In clinical trials, the cannabinoid receptor agonist nabilone significantly reduced levodopainduced dyskinesia in PD. Advanced grades of HD showed an almost total loss of CB1 receptors and a further depletion of Dl receptors in the caudate nucleus, putamen, and globus pallidus internus, and an increase in GABA A receptor binding in the globus pallidus internus.

    Indeed, arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of HD generated by bilateral intrastriatal application of 3-nitropropionic acid 3-NP. However, both capsaicin VR1 agonist and CP55, an CB1 agonist had antihyperkinetic activity Quinolinic acid QA is an excitotoxin which, when injected into the rat striatum, reproduces many features of HD by stimulating glutamate outflow.

    Perfusion with WIN 55, significantly and dose-dependently prevented the increase in extracellular glutamate induced by QA. Thus, the stimulation of CB1 receptors might lead to neuroprotective effects against excitotoxic striatal toxicity. Tourette syndrome TS is a complex inherited disorder of unknown etiology, characterized by multiple motor and vocal tics.

    Anecdotal reports have suggested that the use of cannabis might improve tics and behavioral problems in patients with TS. There was a significant improvement of motor tics, vocal tics and obsessive-compulsive behavior after treatment with THC. Amyotrophic lateral sclerosis ALS is a fatal neurodegenerative disorder characterized by a selective loss of motor neurons in the spinal cord, brain stem, and motor cortex.

    Many effects of marijuana may be applicable to the management of ALS. These include analgesia, muscle relaxation, bronchodilation, saliva reduction, appetite stimulation, and sleep induction. In addition, its strong antioxidative and neuroprotective effects may prolong neuronal cell survival. Furthermore, genetic ablation of the FAAH enzyme, which results in raised levels of the endocannabinoid anandamide, prevented the appearance of disease signs in these mice.

    Ablation of the CB1 receptor, in contrast, had no effect on disease onset in these mice, but significantly extended life span. Together these results show that cannabinoids have significant neuroprotective effects in this model of ALS, and suggest that these beneficial effects may be mediated by nonCB1 receptor mechanisms. Administration at the onset of tremors delayed motor impairment in treated mice when compared with vehicle controls ; moreover, AM prolonged survival in these mice.

    Studies on cannabinoid anticonvulsant activity began in , when CBD, and four CBD derivatives, CBD-aldehyde-diacetate, 6-oxo-CBD-diacetate, 6-hydroxy-CBD-tri-acetate and 9-hydroxy-CBD-triacetate were shown to protect against maximal electroshock convulsions in mice, to potentiate pentobarbital sleeping-time and to reduce spontaneous motor activity.

    Furthermore, it appears that CBD enhances the anticonvulsant effects of drugs in major seizures and reduces their effects in minor seizures. The induction of status epilepticus-like activity by CB1 receptor antagonists was reversible and could be overcome by maximal concentrations of CB1 agonists.

    Cannabis use is common in patients with bipolar disorder, and anecdotal reports suggest that some patients use marijuana to alleviate symptoms of both mania and depression. The effect of cannabinoids on schizophrenia is controversial. Neuropsychological results in THC-intoxicated normal volunteers exhibit strong similarities with data acquired from patients suffering from productive schizophrenic psychoses, as regards disturbances in internal regulation of perceptual processes.

    Data from experimental-psychological tests show that personality changes generated by schizophrenia progression are comparable to psychopathological phenomenon due to cannabis intoxication. This argues against a distinct schizophrenia-like psychosis caused by cannabis. The group receiving the CB1 antagonist did not differ from the group receiving placebo on any outcome measure. CBD causes antipsychotic effects. Posttraumatic stress disorder PTSD is a term for severe psychological consequences of exposure to, or confrontation with, stressful, highly traumatic events.

    Cannabinoids are believed to help in such cases. AMtreated animals showed decreased shock-induced reinstatement of fear. SRI blocked the effects of OL, suggesting that endogenous anandamide plays a facilitator role in extinction through a CB1 receptor mechanism of action. However, upon repeated stress or acute severe stress, CB1 receptor deficiency causes persistent behavioral inhibition.

    Repeated bell stress seemed to cause a cumulative fear in CB1 receptor knockout mice. CB1 receptor gene polymorphism is known to modify transcription of the gene. In patients with Parkinson's disease, the presence of two long alleles, with more than 16 repeated AAT trinucleotides in the CNR1 gene, was associated with a reduced prevalence of depression.

    CBD, and some derivatives, were found to cause a selective anxiolytic effect in the elevated plus-maze, within a limited range of doses.

    The effects of marijuana on human sleep patterns were noticed long ago. Asthma is a chronic disease of the respiratory system in which the airway occasionally constricts, becomes inflamed, and is lined with excessive amounts of mucus.

    In animal experiments, after methacholine-induced or exercise-induced bronchospasm, marijuana caused a prompt improvement of the bronchospasm and associated hyperinflation.

    The daily use of THC was not associated with clinical tolerance. Maximal bronchodilatation was achieved more rapidly with salbutamol, but at 1 hour both drugs were equally effective. No cardiovascular or mood disturbance was detected, and plasma total cannabinoids at 15 minutes were not detected by radioimmunoassay.

    The mode of action of THC differed from that of sympathomimetic drugs. In another study, THC induced sympathetic stimulation and parasympathetic inhibition of cardiovascular control pathways. The peak heart rate rise after THC was attenuated by atropine and by propranolol, and nearly abolished by atropine-propranolol pretreatment.

    With repetitive dosing supine bradycardia and decreased blood pressure with tolerance to orthostatic hypotension were observed. A number of studies suggest that there is a correlative, but not necessarily causal, relationship between glaucoma and systemic hypertension. Ocular hypertension OHT refers to any situation in which intraocular pressure is higher than normal, and is the most important risk factor for glaucoma.

    In contrast, noladin ether decreased IOP immediately after topical administration, and no initial IOP increase was observed. CB2 mRNA was undetectable. Ocular toxicity was seen after THC treatment, consisting of conjunctival erythema and chemosis as well as corneal opacification. Although these changes also occurred with marijuana extract, their intensity was much reduced.

    In contrast, no ocular toxicity was apparent during administration of plant cannabinoids other than THC. The results indicate that THC may have value as a hypotonizing ocular drug. The intensity and duration of the arterial and ocular pressure responses to THC were greater in hypertensives than in normotensive patients; the changes in ocular pressure paralleled the changes in blood pressure in glaucoma patients.

    The antiproliferative action of cannabinoids on cancer cells was first noticed in the s. Since then cannabinoids were found to act on various cancer cell lines, through various mechanisms.

    Moreover, cannabinoid challenge decreased the efficiency of glioma stem-like cells to initiate glioma formation in vivo. Activation of these receptors decreased growth, proliferation, angiogenesis, and metastasis, and increased apoptosis, of melanomas in mice. These effects were prevented by blockade of the CB2 cannabinoid receptor or by pharmacologic inhibition of ceramide synthesis de novo.

    THC inhibited tumor-cell proliferation in vitro, decreased tumor-cell Ki67 immunostaining and prolonged the survival time of two of the patients. Many drugs used today can cause addiction and are misused and abused, for example opiates, cocaine, benzodiazepines, barbiturates, cholinergic agonists, ketamine, , dopaminergic agonists, amphetamines, and others. Nevertheless they are still an important part of our pharmacopeia. Marijuana was used for centuries as a medicinal plant, but during the last century, because of its abuse and addictive potential it was taken out of clinical practice.

    Now, we believe that its constituents and related compounds should be brought back to clinical use. The endocannabinoid system is a very complex one and regulates numerous processes, in parallel with other wellknown systems, such as the adrenergic, cholinergic, and dopaminergic systems.

    National Center for Biotechnology Information , U. Journal List Dialogues Clin Neurosci v. Kogan , MSc Natalya M. Author information Copyright and License information Disclaimer. This is an open-access article distributed under the terms of the Creative Commons Attribution License http: This article has been cited by other articles in PMC. Abstract Cannabis sativa L. Abstract Las preparaciones de Cannabis sativa L. Addiction to canabis, and the influence of cannabis on addiction to other substances Marijuana may produce mild dependence in humans.

    Negative effects of cannabis other than addiction There are some negative effects of cannabis use other than addiction, most of them related to alterations of attentional and cognitive functions or other neuropsychological and behavioral effects.

    Therapeutic uses of cannabinoids Obesity, anorexia, emesis Cannabis has been known for centuries to increase appetite and food consumption. Pain Cannabis has been used for millennia as a pain-relieving substance. Multiple sclerosis, neuroprotection, inflammation Inflammation, autoimmune response, demyelination, and axonal damage are thought to participate in the pathogenesis of MS.

    Parkinson's disease, Huntington's disease, Tourette's syndrome, Alzheimer's disease, epilepsy Parkinson's disease PD is a chronic, progressive neurodegenerative disorder. Bipolar disorder, schizophrenia, post-traumatic stress disorder PTSD , depression, anxiety, insomnia Cannabis use is common in patients with bipolar disorder, and anecdotal reports suggest that some patients use marijuana to alleviate symptoms of both mania and depression.

    Asthma, cardiovascular disorders, glaucoma Asthma is a chronic disease of the respiratory system in which the airway occasionally constricts, becomes inflamed, and is lined with excessive amounts of mucus.

    Cancer The antiproliferative action of cannabinoids on cancer cells was first noticed in the s. Conclusion Many drugs used today can cause addiction and are misused and abused, for example opiates, cocaine, benzodiazepines, barbiturates, cholinergic agonists, ketamine, , dopaminergic agonists, amphetamines, and others. Early medical use of cannabis. Untersuchung der Cannabis sativa.

    Repertorium fur die Pharmacie. Note sur le haschisch. A historical overview of chemical research on cannabinoids. Isolation, structure and partial synthesis of the active constituent of hashish. J Am Chem Soc. Marihuana, an annotated bibliography. Withdrawal symptoms in cannabis indica addicts. The addictive potential of cannabis. Clinical studies of cannabis tolerance and dependence.

    Ann N Y Acad Sci. Treatment of cannabis use disorders: Cannabis addiction and Telic Dominance Scale. Clinical trial of abstinencebased vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol. Addictive potential of cannabinoids: Failure of Delta 9 -tetrahydrocannabinol and CP 55, to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys.

    Endocannabinoid system and alcohol addiction: Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. SR, a central cannabinoid CB 1 receptor antagonist, blocks the motivational and dopaminereleasing effects of nicotine in rats. The diagnosis of alcohol and cannabis dependence addiction in cocaine dependence addiction. Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans.

    Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. Involvement of cannabinoid CB1 receptors in drug addiction: Rimonabant, a CB1 antagonist, blocks nicotineconditioned place preferences. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: The role of the cannabinoid system in nicotine addiction. Successful control of lipids, kilos and cigarettes].

    Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs. Expert Opin Investig Drugs. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats.

    Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: Cell Mol Life Sci. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. Cognitive functioning of longterm heavy cannabis users seeking treatment.

    Chronic cognitive impairment in users of 'ecstasy' and cannabis. Cannabis use, cognitive performance and mood in a sample of workers. Long-term effects of frequent cannabis use on working memory and attention: Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function.

    Cannabis, the mind and society: Cannabis and cognitive dysfunction: The psychotomimetic effects of intravenous deItatetrahydrocannabinol in healthy individuals: Amotivational syndrome in organic solvent abusers. Characteristics of abnormal behavior induced by delta 9-tetrahydrocannabinol in rats. Psychiatric aspects of cannabis use in adolescents and young adults. Related, induced and associated psychiatric disorders to cannabis.

    Operant acquisition of marihuana in man. Cannabis, motivation, and life satisfaction in an internet sample. Subst Abuse Treat Prev Policy.

    Endocannabinoids in the regulation of appetite and body weight. Endocannabinoids in appetite control and the treatment of obesity. Genetic variations at the endocannabinoid type 1 receptor gene CNR1 are associated with obesity phenotypes in men. J Clin Endocrinol Metab. Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats.

    The role of CB1 receptors in sweet versus fat reinforcement: SR , a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.

    Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: Eur J Heart Fail.

    Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: Rimonabant in obese patients with type 2 diabetes. Am J Health Syst Pharm. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage.

    Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Dronabinol effects on weight in patients with HIV infection. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. Cannabinoids in the treatment of the cachexiaanorexia syndrome in palliative care patients.

    A phase II study of deltatetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. Mechanism of action of cannabinoids: An efficient new cannabinoid antiemetic in pediatric oncology. Cannabinoids for control of chemotherapy induced nausea and vomiting: Therapeutic potential of cannabinoids in trigeminal neuralgia. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res.

    Are oral cannabinoids safe and effective in refractory neuropathic pain? Lack of analgesic efficacy of oral deItatetrahydrocannabinol in postoperative pain. Pain relief with oral cannabinoids in familial Mediterranean fever. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis?

    Randomised double blind placebo controlled crossover trial. Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis - secondary publication. The analgesic properties of deItatetrahydrocannabinol and codeine.

    Analgesic effect of deItatetrahydrocannabinol. Cannabis use for chronic non-cancer pain: Cannabis use in HIV for pain and other medical symptoms. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: Cannabimimetic properties of ajulemic acid.

    A tale of two cannabinoids: Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin.

    Initial experiences with medicinal extracts of cannabis for chronic pain: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Combined cannabinoid therapy via an oromucosal spray. Cannabinoids for the treatment of pain: An update on recent clinical trials. Dexanabinol HU effect on experimental autoimmune encephalomyelitis: Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.

    Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Marihuana as a therapeutic agent for muscle spasm or spasticity. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. DeltaTHC in the treatment of spasticity associated with multiple sclerosis.

    Adv Alcohol Subst Abuse. Nabilone in the treatment of multiple sclerosis. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. Treatment of human spasticity with deltatetrahydrocannabinol.

    The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: Int J Clin Pharmacol Ther. Tremor in multiple sclerosis. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Tetrahydrocannabinol for tremor in multiple sclerosis. The effect of cannabis on tremor in patients with multiple sclerosis. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis.

    The effect of cannabis on urge incontinence in patients with multiple sclerosis: Curr Opin Investig Drugs. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis?

    A double-blind, randomized, placebo-controlled study on patients. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis CAMS study: Cannabinoids in multiple sclerosis CAMS study: J Neurol Neurosurg Psychiatry.

    From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches. Cannabinoids in MS - are we any closer to knowing how best to use them? The Cannabis Health Index CHI is an evidence-based scoring system for cannabis in general, not just CBD oil effects and its effectiveness on various health issues based on currently available research data. Using this rubric and based on eleven studies, cannabis rated in the possible-to-probable range of efficacy for treatment of anxiety.

    Elixinol Organic High Potency CBD Capsules Elixinol offers a highly concentrated, high-potency, organic whole-hemp plant CBD oil , which is naturally extracted with carbon dioxide and free of all synthetics and chemicals. Whole-hemp plant extracts contain synergistic compounds that are believed to enhance the effectiveness and benefits of CBD.

    Clinical depression is a serious mood disorder characterized by persistent sadness and loss of interest, sometimes leading to decreased appetite and energy and suicidal thoughts. Commonly used pharmaceuticals for depression often target serotonin, a chemical messenger that is believed to act as a mood stabilizer.

    The neural network of the endocannabinoid system works similarly to the way that serotonin, dopamine, and other systems do, and, according to some research, cannabinoids have an effect on serotonin levels. Whereas a low dose of THC increases serotonin, high doses cause a decrease that could worsen the condition. CBD products with a ratio of Specifically, products made with Valentine X or Electra 4 are more energizing, helping relieve depression.

    When low energy is an issue, sativa or other stimulating strains can be helpful for improving energy and focus when THC can be tolerated. Varieties that are high in the terpene limonene are recommended for mood elevation. Always start with the micro dose to test sensitivity and go up as needed within the dosing range before going to the next, until symptoms subside.

    The micro to standard dose is usually recommended to treat depression. Vaporized or smoked cannabis is recommended for relief of immediate symptoms, or a boost in dosage, and it can also be useful for sleep issues.

    The Cannabis Health Index CHI is an evidence-based scoring system for cannabis in general, not just CBD effects and its effectiveness on various health issues based on currently available research data. Using this rubric and based on twenty-one studies, cannabis rated in the possible-to-probable range of efficacy for treatment of depression. Research in called for clinical trials to look into the effectiveness of cannabinoids for bipolar disorder manic depression.

    It also works on the GABA-glutamate system and the hypothalamic-pituitary-adrenal axis. Its main role is restoring balance through inhibition when levels are too high and enhancement when they are too low. This is the most likely reason phytocannabinoids in general and CBD specifically are able to regulate depression and anxiety.

    The scientific inquiry into cannabis over the past several decades has confirmed that it is an effective and safe analgesic for many kinds of pain. Of all the reasons that people use CBD today, pain is the most common. The same can be said of cannabis in general. In the United States, over seventy million people suffer from chronic pain, which is defined as experiencing over one hundred days per year of pain. Physicians differentiate between neuropathic usually chronic and nociceptive pains usually time-limited , and cannabis works on most neuropathic and many nociceptive types of pain.

    A number of studies have demonstrated that the endocannabinoid system is both centrally and peripherally involved in the processing of pain signals. Cannabinoids can be used along with opioid medications, and a number of studies have demonstrated that they can reduce the amount of opioids needed, lessen the buildup of tolerance, and reduce the severity of withdrawal.

    It is suggested that patients work with a health care practitioner experienced in recommending CBD oil or medicinal cannabis so that dosage and delivery methods can be developed and fine-tuned on an individual basis.

    Oral CBD products with a ratio of Most discussions of treating pain with CBD suggest that finding the right dosage is critical. Always start with the micro dose to test sensitivity and go up as needed within the dosing range by body weight until symptoms subside. If CBD-dominant products alone are not enough to treat a particular case, products with a higher ratio of THC are sometimes recommended to better manage pain.

    For day use, more stimulating, sativa varieties with higher concentrations of myrcene could be added to the formula. In general, for pain, and especially for evening and nighttime, indica strains are favored for their relaxing, sedative effect.

    A person without experience with THC should use caution and titrate slowly up to higher doses. Research as well as patient feedback have indicated that, in general, a ratio of 4: THC is the most effective for both neuropathic and inflammatory pain.

    Each individual is different, however—for some, a 1: Chemotypes high in beta-caryophyllene, myrcene, and linalool provide additional pain relief and increase the effectiveness of other cannabinoids for analgesia. For relief of immediate symptoms, as in a flare-up of pain, vaporizing or smoking work well.

    The medication effect is immediate and lasts one to three hours, whereas most ingested products take thirty to sixty minutes before taking effect faster on an empty stomach and last six to eight hours. Sublingual sprays or tinctures taken as liquid drops also take effect quickly and last longer than inhaled products.

    When pain is localized, topical products can be applied. Topicals affect the cells near application and through several layers of tissue but do not cross the blood-brain barrier and are, therefore, not psychoactive. The skin has the highest amount and concentration of CB2 receptors in the body. Considering all of the studies together, which number over forty for various types of pain , CBD and cannabis are shown to have a rating of likely probable efficacy.

    It is one of the best-substantiated medical uses of cannabinoids. Sativex, a cannabis plant—derived oromucosal spray containing equal proportions of THC and CBD, has been approved in a number of countries for use to treat specific types of pain. Numerous randomized clinical trials have demonstrated the safety and efficacy of Sativex for treatment of central and peripheral neuropathic pain, rheumatoid arthritis, and cancer pain.

    A study showed that CBD and CBC stimulated descending pain-blocking pathways in the nervous system and caused analgesia by interacting with several target proteins involved in nociceptive control. Sleep Disorders Insomnia, Sleep Apnea Cannabis and sleep have a complex relationship that is only beginning to be understood by science. In general, for most people, indica strains are more relaxing and effective for sleep disorders, whereas sativa strains are more stimulating and tend to keep people awake.

    Several studies conducted between and demonstrated the variable effect of different cannabinoids on sleep. Another study found CBD to be wake-inducing for most subjects, though some reported better sleep a few hours after taking it. However, a significant number of people find THC, even indica strains, will make the mind more active.

    For these people, CBD oil can benefit them and tends to work well, providing the relaxation and calm for the mental as well as the physical body. For these people, CBD taken at nighttime as part of a bedtime regime produces a restful sleep, not the alertness produced in the daytime. This bidirectional effect of CBD is the result of balancing the endocannabinoid system.

    In relation to sleep apnea, a animal study observed the ability of THC to restore respiratory stability by modulating serotonin signaling and reducing spontaneous sleep-disordered breathing. It is suggested that patients work with a health care practitioner experienced in recommending CBD or medicinal cannabis so that dosage and delivery methods can be developed and fine-tuned on an individual basis.

    As mentioned previously, while CBD-dominant products help some people sleep, in others it promotes wakefulness. These tend to be high in myrcene and linalool, a terpene shared with lavender and known to be effective for relaxation.

    Cannabis combinations with ratios of 1: THC can be used when patients want to reduce psychoactivity. Oral consumption is recommended as it usually lasts the whole night. The micro to standard dose is usually recommended to treat insomnia and sleep apnea.

    When relaxing indica strains are used with higher THC levels, a dose of 5—10 mg is usually sufficient. Other people find they need larger doses, such as 15—40 mg. CBD taken as a tincture or edible will aid in a restful six to seven hours of sleep. This type of disorder varies widely from one patient to the next.

    Often, one needs to perform some experimental research and try strains of different CBD: For immediate medicinal effects, vaporizing or smoking work well.

    This can be helpful for either initial sleep onset or for wakefulness in the middle of a rest period but only lasts one to three hours. The medication effect is immediate, whereas most ingested products take thirty to sixty minutes before taking effect faster on an empty stomach and last six to eight hours. Vaporizers that use a cartridge filled with the CO2 concentrate are convenient and highly effective, and these are available in various ratios of CBD to THC.

    Using this rubric, the use of cannabis-based products for treating insomnia has a rating of likely probable efficacy based on the four studies available at press time 3. A study with the pharmaceutical 1: THC spray showed good results in helping patients with chronic pain sleep better. Four patients in a case series treated with CBD in had prompt and substantial reduction in the frequency of RBD-related events without side effects.

    The Dana Forum on Brain Science Trends in Pharmacological Science 36, no.

    Does CBD oil work for chronic pain management?

    Nov 29, Discover the science behind CBD (cannabidiol), and how to get the most out of Only cannabis with less than % THC can be legally classified as hemp. Cannabinoids, including cannabidiol (CBD), work by mimicking natural . Usually purity is a good thing, but in this case, purified CBD is missing all. Sep 10, Does it work? Before diving in, feel free to check out the first part of the series, where many have posited that cannabinoids like THC or CBD could help Clinical trials are still confirming the efficacy of CBD oil, but many. Learn all about CBD oil a naturally occurring compound found in the Many people want the health benefits of cannabis without the high – or with less of a high. The fact These “endocannabinoids” are part of a regulatory system called the as a real medicine by approving Epidiolex, an almost pure pharmaceutical CBD.

    What is CBD and What Medical Conditions Might It Help?



    Comments

    erickyagami

    Nov 29, Discover the science behind CBD (cannabidiol), and how to get the most out of Only cannabis with less than % THC can be legally classified as hemp. Cannabinoids, including cannabidiol (CBD), work by mimicking natural . Usually purity is a good thing, but in this case, purified CBD is missing all.

    academik

    Sep 10, Does it work? Before diving in, feel free to check out the first part of the series, where many have posited that cannabinoids like THC or CBD could help Clinical trials are still confirming the efficacy of CBD oil, but many.

    Add Comment